Daily cannabis use during the novel coronavirus disease (COVID-19) pandemic in Canada: a repeated cross-sectional study from May 2020 to December 2020.

Adult COVID-19 Canada / epidemiology Cannabis / adverse effects Cross-Sectional Studies Humans Pandemics SARS-CoV-2
COVID-19 Canada Cannabis Coronavirus Marijuana SARS-CoV-2

Journal

Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060

Informations de publication

Date de publication:
21 02 2022
Historique:
accepted: 08 02 2022
entrez: 22 2 2022
pubmed: 23 2 2022
medline: 26 2 2022
Statut: epublish

Résumé

Daily cannabis use is most strongly implicated in the cannabis-attributable burden of disease. In the context of the novel coronavirus disease (COVID-19) pandemic in Canada, we characterized trends in daily cannabis use in the overall sample and various population subgroups, and examined risk characteristics associated with daily cannabis use. A cross-sectional design was operationalized using data from six waves of a national, online survey of adults residing in Canada who spoke English (N = 6,021; May-08 2020 to December-01 2020). Trends were characterized using the Cochran-Armitage test and risk characteristics were identified using chi-square test and logistic regression analysis. Daily cannabis use in the overall sample remained stable (5.34% - 6.10%; p = 0.30). This pattern of findings extended to various population subgroups as well. The odds of daily cannabis use were higher for those who: were males (Odds Ratio; 95% Confidence Interval: 1.46; 1.15 - 1.85), were between 18 - 29 years (2.36; 1.56 - 3.57), 30 - 39 years (2.65; 1.93 - 3.64) or 40-49 years (1.74; 1.19 - 2.54), self-identified as white (1.97; 1.47 - 2.64), had less than college or university completion (1.78; 1.39 - 2.28), engaged in heavy episodic drinking (2.05; 1.62 - 2.61), had a job that increased the risk of contracting COVID-19 (1.38; 1.01 - 1.88), experienced loneliness 5-7 days in the past week (1.86; 1.26 - 2.73) and felt very worried (2.08; 1.21 - 3.58) or somewhat worried (1.83; 1.11 - 3.01) about the pandemic's impact on their financial situation. Daily cannabis use did not change in the overall sample or various population subgroups during the pandemic. Pandemic-related risks and impacts were associated with daily cannabis use.

Sections du résumé

BACKGROUND
Daily cannabis use is most strongly implicated in the cannabis-attributable burden of disease. In the context of the novel coronavirus disease (COVID-19) pandemic in Canada, we characterized trends in daily cannabis use in the overall sample and various population subgroups, and examined risk characteristics associated with daily cannabis use.
METHODS
A cross-sectional design was operationalized using data from six waves of a national, online survey of adults residing in Canada who spoke English (N = 6,021; May-08 2020 to December-01 2020). Trends were characterized using the Cochran-Armitage test and risk characteristics were identified using chi-square test and logistic regression analysis.
RESULTS
Daily cannabis use in the overall sample remained stable (5.34% - 6.10%; p = 0.30). This pattern of findings extended to various population subgroups as well. The odds of daily cannabis use were higher for those who: were males (Odds Ratio; 95% Confidence Interval: 1.46; 1.15 - 1.85), were between 18 - 29 years (2.36; 1.56 - 3.57), 30 - 39 years (2.65; 1.93 - 3.64) or 40-49 years (1.74; 1.19 - 2.54), self-identified as white (1.97; 1.47 - 2.64), had less than college or university completion (1.78; 1.39 - 2.28), engaged in heavy episodic drinking (2.05; 1.62 - 2.61), had a job that increased the risk of contracting COVID-19 (1.38; 1.01 - 1.88), experienced loneliness 5-7 days in the past week (1.86; 1.26 - 2.73) and felt very worried (2.08; 1.21 - 3.58) or somewhat worried (1.83; 1.11 - 3.01) about the pandemic's impact on their financial situation.
CONCLUSIONS
Daily cannabis use did not change in the overall sample or various population subgroups during the pandemic. Pandemic-related risks and impacts were associated with daily cannabis use.

Identifiants

DOI: 10.1186/s13011-022-00441-x PMID: 35189909 PMC: PMC8860264
pubmed: 35189909
doi: 10.1186/s13011-022-00441-x
pii: 10.1186/s13011-022-00441-x
pmc: PMC8860264
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14

Informations de copyright

© 2022. The Author(s).

Références

JAMA Netw Open. 2021 Nov 1;4(11):e2133076
pubmed: 34735016
Can J Psychiatry. 2021 Sep;66(9):815-826
pubmed: 33464115
Addiction. 2016 Apr;111(4):653-62
pubmed: 26598973
Drug Alcohol Depend. 1998 Aug 1;51(3):253-63; discussion 267-8
pubmed: 9787998
Health Rep. 2020 Feb 19;31(2):11-20
pubmed: 32073644
Am J Public Health. 2017 Aug;107(8):e1-e12
pubmed: 28644037
Can J Public Health. 2018 Jan 22;108(5-6):e516-e522
pubmed: 29356658
Can J Psychiatry. 2021 Jan;66(1):56-58
pubmed: 32787572
J Public Health (Oxf). 2016 Mar;38(1):183-8
pubmed: 25630540
Subst Abus. 2020;41(4):409-412
pubmed: 33044893
Addiction. 2016 Oct;111(10):1856-66
pubmed: 27206790
CMAJ. 2020 May 11;192(19):E497-E505
pubmed: 32269018
Health Rep. 2021 Apr 21;32(4):3-14
pubmed: 33881274
Can J Public Health. 2020 Dec;111(6):953-962
pubmed: 33170494
J Stud Alcohol. 2006 Mar;67(2):318-23
pubmed: 16562415
J Addict Med. 2021 Nov-Dec 01;15(6):484-490
pubmed: 33323693
Addict Behav Rep. 2021 Mar 03;13:100341
pubmed: 33763517
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Eur Neuropsychopharmacol. 2020 Apr;33:1-35
pubmed: 32165103
Can J Public Health. 2011 Sep-Oct;102(5):324-7
pubmed: 22032094
Curr Addict Rep. 2017 Jun;4(2):184-193
pubmed: 32670740

Auteurs

Sameer Imtiaz (S)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada. sameer.imtiaz@camh.ca.
ORCID: 0000-0001-6812-4892

Samantha Wells (S)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Dalla Lana School of Public Health, University of Toronto, 6th Floor, 155 College Street, Toronto, ON, M5T 3M7, Canada.
Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, Kresge Building, London, ON, N6A 5C1, Canada.

Jürgen Rehm (J)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Dalla Lana School of Public Health, University of Toronto, 6th Floor, 155 College Street, Toronto, ON, M5T 3M7, Canada.
Institute of Medical Science, University of Toronto, Room 2374, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada.
Department of Psychiatry, University of Toronto, 8th Floor, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Institute for Clinical Psychology and Psychotherapy, TU Dresden, Chemnitzer Str. 46, 01187, Dresden, Germany.
Department of International Health Projects, Institute for Leadership and Health Management, I.M. Sechenov First Moscow State Medical University, Trubetskaya Str., 8, B. 2, 119992, Moscow, Russian Federation.

Christine M Wickens (CM)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Dalla Lana School of Public Health, University of Toronto, 6th Floor, 155 College Street, Toronto, ON, M5T 3M7, Canada.
Institute of Health Policy, Management and Evaluation, University of Toronto, 425-155 College Street, Toronto, ON, M5T 1P8, Canada.
Department of Pharmacology & Toxicology, University of Toronto, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada.

Hayley Hamilton (H)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Dalla Lana School of Public Health, University of Toronto, 6th Floor, 155 College Street, Toronto, ON, M5T 3M7, Canada.

Yeshambel T Nigatu (YT)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.

Damian Jankowicz (D)

Information Management, Centre for Addiction and Mental Health, 1001 Queen Street West, Toronto, ON, M6J 1H4, Canada.

Tara Elton-Marshall (T)

Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, 33 Russell Street, ON, M5S 2S1, Toronto, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Dalla Lana School of Public Health, University of Toronto, 6th Floor, 155 College Street, Toronto, ON, M5T 3M7, Canada.
Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, Kresge Building, London, ON, N6A 5C1, Canada.
Department of Health Sciences, Lakehead University, SN 1006, 955 Oliver Road, Thunder Bay, ON, P7B 5E1, Canada.
School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON, K1G 5Z3, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Daily cannabis use during the novel...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Daily cannabis use during the novel...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › Canada › Daily cannabis use during the novel...
questionsmedicales.fr › Eucaryotes › Viridiplantae › Streptophyta › Embryophyta › Tracheobionta › Magnoliopsida › Rosanae › Rosales › Cannabaceae › Cannabis › Daily cannabis use during the novel...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Daily cannabis use during the novel...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Daily cannabis use during the novel...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Daily cannabis use during the novel...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Daily cannabis use during the novel...